ArticleBMC cancer2011
Prognostic significance of CD44s expression in resected non-small cell lung cancer.
Article in BMC cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Prognostic value of CD44 and CD44v6 expression in patients with non-small cell lung cancer: meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Prognostic value of CD44 expression in non-small cell lung cancer: a systematic review.International journal of clinical and experimental pathology · 2014Pooled it
- Prognostic significance of CD44s expression in oral squamous cell carcinoma: An immuno-histo-chemical analysis.Bioinformation · 2025Article
- The Tumor Immune Microenvironment Is Associated With Recurrence in Early-Stage Lung Adenocarcinoma.JTO clinical and research reports · 2024Article
- Cisplatin-Resistant CD44International journal of molecular sciences · 2022Article
- Article
- Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion.Theranostics · 2022Article
- A global cancer data integrator reveals principles of synthetic lethality, sex disparity and immunotherapy.Genome medicine · 2021Article
- [Expression of CD44 in Tumor Tissue and Serum of Small Cell Lung Cancer and Its Clinical Prognostic Significance].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2021Article
- Extracellular matrix and its therapeutic potential for cancer treatment.Signal transduction and targeted therapy · 2021Review
- Emodin regulates cell cycle of non-small lung cancer (NSCLC) cells through hyaluronan synthase 2 (HA2)-HA-CD44/receptor for hyaluronic acid-mediated motility (RHAMM) interaction-dependent signaling pathway.Cancer cell international · 2021Article
- The Role of the ECM in Lung Cancer Dormancy and Outgrowth.Frontiers in oncology · 2020Review
- Hyaluronan-CD44/RHAMM interaction-dependent cell proliferation and survival in lung cancer cells.Molecular carcinogenesis · 2019Article
- CD44 splice isoform switching determines breast cancer stem cell state.Genes & development · 2019Article
- Smad3-related miRNAs regulated oncogenic TRIB2 promoter activity to effectively suppress lung adenocarcinoma growth.Cell death & disease · 2016Article
- Intratracheal Administration of Hyaluronan-Cisplatin Conjugate Nanoparticles Significantly Attenuates Lung Cancer Growth in Mice.Pharmaceutical research · 2016Article
- ZEB1 drives epithelial-to-mesenchymal transition in lung cancer.The Journal of clinical investigation · 2016Article
- Impact and mechanism of non-steroidal anti-inflammatory drugs combined with chemotherapeutic drugs on human lung cancer-nude mouse transplanted tumors.Oncology letters · 2016Article
- Positive association between CD44 gene rs13347 C>T polymorphism and risk of cancer in Asians: a systemic review and meta-analysis.OncoTargets and therapy · 2016Article
- Association of CD44 Gene Polymorphism with Survival of NSCLC and Risk of Bone Metastasis.Medical science monitor : international medical journal of experimental and clinical research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCD44s is a cell adhesion molecule known to mediate cellular adhesion to the extracellular matrix, a prerequisite for tumor cell migration. CD44s plays an important role in invasion and metastasis of various cancers. In the present study, we sought to determine whether CD44s is involved in clinical outcomes of patients with resected non-small cell lung cancer (NSCLC).
methodsUsing immunohistochemical staining, we investigated CD44s protein expression using tissue array specimens from 159 patients with resected NSCLC (adenocarcinoma (AC; n=82) and squamous cell carcinoma (SCC; n=77). Additionally, the immunoreactivity of cyclooxygenase (COX)-2 was also studied. The clinicopathological implications of these molecules were analyzed statistically.
resultsHigh CD44s expression was detected more frequently in NSCLC patients with SCC (66/72; 91.7%) than in those with AC histology (P<0.001). Additionally, high CD44s expression was significant correlated with more advanced regional lymph node metastasis (P=0.021). In multivariate analysis of survival in NSCLC patients with AC histology, significant predictors were lymph node metastasis status (P<0.001), high-grade tumor differentiation (P=0.046), and high CD44s expression (P=0.014). For NSCLC patients with SCC histology, the significant predictor was a more advanced tumor stage (P=0.015). No significant association was found between CD44s and clinical outcome (P=0.311).
conclusionsHigh CD44s expression was a negative prognostic marker with significance in patients with resected NSCLC, particularly those with AC histology, and was independent of tumor stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.